• Something wrong with this record ?

Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy

SF. Ameriso, P. Amarenco, LA. Pearce, KS. Perera, G. Ntaios, W. Lang, D. Bereczki, S. Uchiyama, SE. Kasner, BW. Yoon, P. Lavados, A. Firstenfeld, R. Mikulik, GP. Povedano, J. Ferrari, H. Mundl, SD. Berkowitz, SJ. Connolly, RG. Hart,

. 2020 ; 29 (8) : 104936. [pub] 20200608

Language English Country United States

Document type Clinical Trial, Phase III, Comparative Study, Journal Article, Multicenter Study, Randomized Controlled Trial

Persistent link   https://www.medvik.cz/link/bmc20027978

BACKGROUND: Non-stenotic intracranial and systemic atherosclerosis are associated with ischemic stroke. We report frequency and response to anticoagulant vs. antiplatelet prophylaxis of patients with embolic stroke of undetermined source (ESUS) who have non-stenotic intracranial atherosclerosis and/or systemic atherosclerosis. METHODS: Exploratory analysis of the international NAVIGATE ESUS randomized trial comparing rivaroxaban 15mg daily with aspirin 100mg daily in 7213 patients with recent ESUS. Among participants with results of intracranial arterial imaging with either computed tomographic angiography (CTA) or magnetic resonance angiography (MRA), the frequency and predictors of non-stenotic intracranial and systemic atherosclerosis and responses to antithrombotic therapy were assessed. RESULTS: Among 4723 participants with available intracranial CTA or MRA results (65% of the trial cohort), the prevalence of intracranial atherosclerosis was 16% (n=739). Patient features independently associated with intracranial atherosclerosis included East Asian region (odds ratio 2.7, 95%CI 2.2,3.3) and cervical carotid plaque (odds ratio 2.3, 95%CI 1.9,2.7), among others. The rate of recurrent ischemic stroke averaged 4.8%/year among those with intracranial atherosclerosis vs. 5.0.%/year for those without (HR 0.95, 95%CI 0.65, 1.4). Among those with intracranial atherosclerosis, the recurrent ischemic stroke rate was higher if assigned to rivaroxaban (5.8%/year) vs. aspirin (3.7%/year), but the difference was not statistically significant (HR 1.6, 95%CI 0.78, 3.3). There was trend for the effect of antithrombotic treatments to be different according to the presence or absence of intracranial atherosclerosis (pinteraction=0.09). Among participants with evidence of systemic atherosclerosis by either history or imaging (n=3820), recurrent ischemic stroke rates were similar among those assigned to rivaroxaban (5.5%/year) vs. aspirin (4.9%/year)(HR 1.1, 95%CI 0.84, 1.5). CONCLUSIONS: East Asia region was the strongest factor associated with intracranial atherosclerosis. There were no statistically significant differences between rivaroxaban and aspirin prophylaxis for recurrent ischemic stroke in patients with non-stenotic intracranial atherosclerosis and/or systemic atherosclerosis.

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc20027978
003      
CZ-PrNML
005      
20210114152728.0
007      
ta
008      
210105s2020 xxu f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.jstrokecerebrovasdis.2020.104936 $2 doi
035    __
$a (PubMed)32689594
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a xxu
100    1_
$a Ameriso, Sebastian F $u Institute for Neurological Research-FLENI, Buenos Aires, Argentina. Electronic address: sameriso@fleni.org.ar.
245    10
$a Intracranial and systemic atherosclerosis in the NAVIGATE ESUS trial: Recurrent stroke risk and response to antithrombotic therapy / $c SF. Ameriso, P. Amarenco, LA. Pearce, KS. Perera, G. Ntaios, W. Lang, D. Bereczki, S. Uchiyama, SE. Kasner, BW. Yoon, P. Lavados, A. Firstenfeld, R. Mikulik, GP. Povedano, J. Ferrari, H. Mundl, SD. Berkowitz, SJ. Connolly, RG. Hart,
520    9_
$a BACKGROUND: Non-stenotic intracranial and systemic atherosclerosis are associated with ischemic stroke. We report frequency and response to anticoagulant vs. antiplatelet prophylaxis of patients with embolic stroke of undetermined source (ESUS) who have non-stenotic intracranial atherosclerosis and/or systemic atherosclerosis. METHODS: Exploratory analysis of the international NAVIGATE ESUS randomized trial comparing rivaroxaban 15mg daily with aspirin 100mg daily in 7213 patients with recent ESUS. Among participants with results of intracranial arterial imaging with either computed tomographic angiography (CTA) or magnetic resonance angiography (MRA), the frequency and predictors of non-stenotic intracranial and systemic atherosclerosis and responses to antithrombotic therapy were assessed. RESULTS: Among 4723 participants with available intracranial CTA or MRA results (65% of the trial cohort), the prevalence of intracranial atherosclerosis was 16% (n=739). Patient features independently associated with intracranial atherosclerosis included East Asian region (odds ratio 2.7, 95%CI 2.2,3.3) and cervical carotid plaque (odds ratio 2.3, 95%CI 1.9,2.7), among others. The rate of recurrent ischemic stroke averaged 4.8%/year among those with intracranial atherosclerosis vs. 5.0.%/year for those without (HR 0.95, 95%CI 0.65, 1.4). Among those with intracranial atherosclerosis, the recurrent ischemic stroke rate was higher if assigned to rivaroxaban (5.8%/year) vs. aspirin (3.7%/year), but the difference was not statistically significant (HR 1.6, 95%CI 0.78, 3.3). There was trend for the effect of antithrombotic treatments to be different according to the presence or absence of intracranial atherosclerosis (pinteraction=0.09). Among participants with evidence of systemic atherosclerosis by either history or imaging (n=3820), recurrent ischemic stroke rates were similar among those assigned to rivaroxaban (5.5%/year) vs. aspirin (4.9%/year)(HR 1.1, 95%CI 0.84, 1.5). CONCLUSIONS: East Asia region was the strongest factor associated with intracranial atherosclerosis. There were no statistically significant differences between rivaroxaban and aspirin prophylaxis for recurrent ischemic stroke in patients with non-stenotic intracranial atherosclerosis and/or systemic atherosclerosis.
650    _2
$a senioři $7 D000368
650    _2
$a Aspirin $x aplikace a dávkování $x škodlivé účinky $7 D001241
650    _2
$a dvojitá slepá metoda $7 D004311
650    _2
$a inhibitory faktoru Xa $x aplikace a dávkování $x škodlivé účinky $7 D065427
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a fibrinolytika $x aplikace a dávkování $x škodlivé účinky $7 D005343
650    _2
$a lidé $7 D006801
650    _2
$a intrakraniální arterioskleróza $x diagnostické zobrazování $x farmakoterapie $x epidemiologie $7 D002537
650    _2
$a intrakraniální embolie $x diagnostické zobrazování $x epidemiologie $x prevence a kontrola $7 D020766
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a onemocnění periferních arterií $x diagnostické zobrazování $x farmakoterapie $x epidemiologie $7 D058729
650    _2
$a inhibitory agregace trombocytů $x aplikace a dávkování $x škodlivé účinky $7 D010975
650    _2
$a prevalence $7 D015995
650    _2
$a recidiva $7 D012008
650    _2
$a hodnocení rizik $7 D018570
650    _2
$a rizikové faktory $7 D012307
650    _2
$a rivaroxaban $x aplikace a dávkování $x škodlivé účinky $7 D000069552
650    _2
$a cévní mozková příhoda $x diagnostické zobrazování $x epidemiologie $x prevence a kontrola $7 D020521
650    _2
$a časové faktory $7 D013997
650    _2
$a výsledek terapie $7 D016896
655    _2
$a klinické zkoušky, fáze III $7 D017428
655    _2
$a srovnávací studie $7 D003160
655    _2
$a časopisecké články $7 D016428
655    _2
$a multicentrická studie $7 D016448
655    _2
$a randomizované kontrolované studie $7 D016449
700    1_
$a Amarenco, Pierre $u Department of Neurology, Bichat Hospital, Paris University, Paris, France.
700    1_
$a Pearce, Lesly A $u Biostatistics Consultant, Minot, ND, USA.
700    1_
$a Perera, Kanjana S $u Department of Medicine (Neurology), McMaster University/Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada.
700    1_
$a Ntaios, George $u Department of Medicine, University of Thessaly, Larissa, Greece.
700    1_
$a Lang, Wilfried $u Medical Faculty, Hospital St. John of God, Sigmund Freud Private University, Vienna, Austria.
700    1_
$a Bereczki, Daniel $u Department of Neurology, Semmelweis University, Budapest, Hungary.
700    1_
$a Uchiyama, Shinichiro $u International University of Health and Welfare, Sanno Hospital and Sanno Medical Center, Tokyo, Japan.
700    1_
$a Kasner, Scott E $u Department of Neurology, University of Pennsylvania, Philadelphia, PA, USA.
700    1_
$a Yoon, Byung-Woo $u Department of Neurology, Seoul National University Hospital, Seoul, Korea.
700    1_
$a Lavados, Pablo $u Clinica Alemana de Santiago, Universidad del Desarrollo, Santiago, Chile.
700    1_
$a Firstenfeld, Alfredo $u Instituto Cardiologico Banfield, Buenos Aires, Argentina.
700    1_
$a Mikulik, Robert $u International Clinical Research Center and Neurology Department, St. Anne's University Hospital and Masaryk University, Brno, Czech Republic.
700    1_
$a Povedano, Guillermo Pablo $u Complejo Medico de la PFA Churruca Visca, Buenos Aires, Argentina.
700    1_
$a Ferrari, Jorge $u Hospital Interzonal General de Agudos Eva Peron, Buenos Aires, Argentina.
700    1_
$a Mundl, Hardi $u Bayer AG, Wuppertal, Germany.
700    1_
$a Berkowitz, Scott D $u Pharmaceuticals Clinical Development Thrombosis, Bayer U.S. LLC, Whippany, NJ, USA.
700    1_
$a Connolly, Stuart J $u Department of Medicine (Cardiology), McMaster University / Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada.
700    1_
$a Hart, Robert G $u Population Health Research Institute, Hamilton Health Sciences, Hamilton, Ontario, Canada.
773    0_
$w MED00167194 $t Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association $x 1532-8511 $g Roč. 29, č. 8 (2020), s. 104936
856    41
$u https://pubmed.ncbi.nlm.nih.gov/32689594 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y a $z 0
990    __
$a 20210105 $b ABA008
991    __
$a 20210114152725 $b ABA008
999    __
$a ok $b bmc $g 1608313 $s 1119158
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2020 $b 29 $c 8 $d 104936 $e 20200608 $i 1532-8511 $m Journal of stroke and cerebrovascular diseases $n J Stroke Cerebrovasc Dis $x MED00167194
LZP    __
$a Pubmed-20210105

Find record

Citation metrics

Archiving options